I published 7 manuscripts based on my dissertation work, 4 of which are first-author, on the ubiquitin proteasome system in cardiac and skeletal muscle diseases. Specifically, my work focused on muscle atrophy-associated ubiquitin ligases that regulate nuclear receptor transcription factors in cardiac hypertrophy. My dissertation work was funded by a Predoctoral grant awarded to me by the American Heart Association. In addition, I have given several oral presentations at national meetings on this topic, for which I received trainee travel grants from both the American Society for Investigative Pathology and American Physiological Society.
I came to Roswell Park Cancer Institute in January 2015, joining the laboratory of Dr. Shahriar Koochekpour to study the mechanisms governing castration-recurrent prostate cancer. Recently, I have published three comprehensive review articles on treatment of advanced prostate cancer and therapy resistance and a research article on how the FDA-approved drug for ALS , riluzole, has anti-tumor effects in prostate cancer. In September 2016, I joined the laboratory of Dr. David Goodrich to study the mechanisms driving neuroendocrine prostate cancer. I presented my current work as a podium presentation at the 2018 Annual Meeting of the American Association for Cancer Research.
Being a first-generation student, I am dedicated to community outreach. Especially in teaching young students with similar backgrounds about opportunities in science, technology, engineering, and math (STEM)."